Through the ROC curve analysis of TBILA and AGAP2-AS1, the results show that in the diagnosis of NSCLC, TBILA has an AUC value of 0.775, AGAP2-AS1 has an AUC value of 0.734, and the AUC value of the combined serum marker Cyfra21-1 is 0.853, indicating that this combination can increase the diagnostic ability of NSCLC (Tao et al., 2020). Here, TBILA is linked to non-small cell lung carcinoma.